Member Info for lukehere

Worth remembering that when the Rentokil Initial deal was signed off,it was envisaged that revenues from this would build to £4million p.a. Bearing in mind the renewed emphasis that Initial are placing on Ultra Protect,its impact on future Byotrol revenues could be sufficient to ensure profitability. The SP is about to climb,imo. A VERY strong buy @ just 6 pence.

I believe the UHCW trial is the first in the UK for Byotrol as a general cleaning agent,rather than any medical orientation. The recently concluded successful trial at the Kent & Midway NHS Social Care Partnership Trust was for healthcare products. The differentiation was a strategic decision by the BYOT BOD to achieve a two pronged approach to the procurement process. ISS are overseeing the use of Byotrol at UHCW and they do hold much of the responsibility the the Trusts Estate. My view is that the trial will prove exceedingly satisfactory,leading to multiple orders. Byotrol remains imo a VERY strong buy,even though the SP has recently strengthened a little.

The University Hospitals of Coventry and Warwickshire are trialing BYOTROL overseen by ISS. UNIVERSITY HOSPITALS of COVENTRY and WARWICKSHIRE. "Working with both ISS and Estates the Trust is aiming to introduce a new cleaning regime and are trialling a new cleaning product for 3 months, this is a product used extensively in the food industry but this is the first healthcare environment to trial Byotrol. Byotrol is a QUAT based agent which leaves a residue that inhibits the build up of organisms. In tests undertaken by the ISS Microbiologist it indicates that with continued use the number of organisms cultured each day was reduced. This does not replace chlorine dioxide (Tristel) which will still be used for barrier, outbreak and C diff issues. It is more cost effective than the general purpose cleaner against which it is being trialled."

Lets not overlook Byotrol's burgeoning impact in this arena !! "Smart Cat PLUS Byotrol is the ultimate antimicrobial wood flour Cat Litter. Our best selling premium Smart Cat litter is further enhanced with the addition of Byotrol - a revolutionary germ killing technology offering supreme hygiene in the tray by killing harmful bacteria. This coupled with the established benefits of Smart Cat ie organic and bodegradable with a natural pine fresh fragrance and manufactured in the UK from reliably sourced local material makes Smart Cat PLUS the ultimate choice for discerning cat owners." A huge variety of pet products, containing Byotrol ,are making an ever increasing impact.....GLOBALLY.

With a large seller currently enabling STL to be bought at just 3.1 pence;it could be worth an investment. Stilo occupies a serious niche in an expanding sector,recently saw a maiden dividend declared,is debt free and has seen Director buying.

Not only are Byotrol formulations gaining an initial foothold within the NHS,they managed to secure a "best product" rating in the latest procurement round. The BYOT share price is also starting to rise. A VERY strong buy imo @the currently available quote of. 4.75 pence.

"Byotrol’s novel capacity to sustain antimicrobial activity on skin and surfaces well after application is quite revolutionary. It really is a powerful message to anyone concerned with hygiene in the workplace." Dr. Peter Barratt PhD. CBiol MSB, Technical Manager, Initial. So much so that RentokilInitial are phasing out their former sanitizers and promoting,relaunching and expanding the Byotrol based Ultra Protect range.

From the Byotrol Interims:- " Our hand hygiene products have been launched with Winch Pharma into UK healthcare under the Athenian brand." Now WinchPharma Group has announced that it has recently won a share of a public NHS tender worth in the region of £39 million from the Normanton NHS Supply Chain. The Normanton NHS Supply Chain supply of non-alcoholic hand sanitisers, and related infection control products was part of a public tender worth approximately £39 million. WinchPharma Group is proud to announce that it has recently won a large share of this tender with its successful Athenian Hygiene infection prevention product lines. Following the successful trial of certain products at the Kent & Midway NHS Social Care Partnership Trust, WinchPharma submitted a strong bid for the above NHS tender, in which it was subsequently awarded the contract framework as a preferred supplier, outranking many multinational competitors.

One man's meat Dubuary. I really enjoy researching,investing in and then following AIM micro-caps. My current big four ,in addition to the so far disappointing BYOT, are SDI, SWP, SNTY and BIOM. They are all exceedingly promising and demonstrating encouraging relative strength. No investment advice intended !

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=BYOT&ArticleCode=bw1v7tc7&ArticleHeadline=Interim_Results

Formal testing of the Byotrol healthcare range is now underway in two UK hospitals and initial results are promising. The tests are being conducted in partnership with ISS, one of the world's leading facility services companies and very active in UK healthcare. (ISS named world's best outsourcing company. The International Association of Outsourcing Professionals has ranked ISS as the #1 on its annual list of the world's best outsourcing service providers.) David Traynor has indicated to me by email that positive news will be forthcoming,when appropriate. IMO BYOT is a particularly interesting investment at current levels.

Byotrol formulations for athletes/hikers etc ,now being sold on every high street in England through Sports Direct.

Agreed clogheen. Whilst the figures revealed in the Interims were disappointing,the CEO's accompanying statement painted a much more promising picture,particularly the news that Byotrol hygiene products are now listed in the NHS supply chain,this being the first time that non-alcohol hand sanitisers have been endorsed for NHS use. This serves to blow out of the water those detractors who claimed that Byotrol was unfit for purpose. Edisons remain guardedly optimistic, "The challenging global consumer climate continues to delay the introduction of new products employing Byotrol technology. Nevertheless, agreements with Rentokill Initial, Albaad, Robert McBride (for Tesco) and Marks & Spencer all underline the success of recent product trials. Restructuring, involving buying out the group's partner in Byotrol Consumer Products and a change in CEO, suggests a positive move towards developing consumer relationships. We continue to look for strong revenue growth over the next two to three years, as new agreements start to deliver. Last updated on 23/12/2013"

If indeed this mornings price of 4.625 proves to be the low point then we already have a double bottom in place. I bought 100k today and it proved a bit of a struggle to obtain the 4.75 buying price.Here is hoping David Traynor works some magic over the coming months.

Possibly ,Dubuary,nice on the face of it. Yet,as we all know,should BYOT go tits up,then there would be no "magic" cash to return to creditors,no matter whether they are preferred;particularly so with Close Brothers holding a Debenture over BYOT fixed and floating assets. imo.

It may seem perverse,yet the more BYOT fall the nearer becomes the rebound,and with it a change in sentiment,whilst the value to be gained from investing at these levels becomes overwhelming;to me anyway. I have been throwing serious cash at the shares today and will continue to do so whilst the SP remains @ 5 pence or below.Others imo would be well served in following suit.

.

Martin’s own career has been at Greenwich NatWest (1993-2001) and Swiss Re (2001-2010), including leading the Legacy Division that successfully dealt with the fallout from the financial markets melt down. Martin currently provides consulting services on complex large insurance / corporate finance transactions, principally to Swiss Reinsurance Company. Martin is a chartered accountant, barrister and New York attorney.

Huge interest and skills links between Rushton-Turner and Delotte partner Pereira,both being tax and legal experts with specialist interest in the banking sector. “European Union state aid rules and sovereign bail-out programmes and changes in business strategy induced by the plethora of reforms faced by the banking sector are also important drivers,” said Deloitte’s Vivian Pereira. “Banks in countries under the IMF/EU/ECB programmes also have additional pressures to deleverage.” Can't help but think that these are our men.

A while ago I made a connection between Rushton -Turner and Pereira,but I am struggling to re establish it. This,I believe is our large holder,JMRT.The initial connection ,I surmise, comes via Standen who was also in wealth management,investment banking with BZW,a division of Barclays PLC.

My best practical indicator for a share bottoming out occurs when one cannot obtain a quote to sell even a modest amount of stock within the spread.This has been apparent over the past few days.BUY !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!